Overleg:Pandemrix: verschil tussen versies
Verwijderde inhoud Toegevoegde inhoud
→Passage over ontkenning RIVM: 3 gevallen te onderzoeken RIVM 2011 |
|||
Regel 39:
https://www.rivm.nl/documenten/rvp-nieuws-4-2011[[Gebruiker:Jc kortekaas apotheker|Jc kortekaas apotheker]] ([[Overleg gebruiker:Jc kortekaas apotheker|overleg]]) 6 jan 2021 18:48 (CET)
****De EMA verwerpt het verband in 2012 , dat uit Scandinavische bronnen komt.
No new concerns for Pandemrix or other vaccines on the basis of available evidence
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), at the request of the Agency's Executive Director Guido Rasi, has reviewed preliminary research results by the Finnish National Institute of Health and Welfare (THL) investigating differences in the immunological response triggered by different pandemic influenza vaccines as a potential root cause for the development of narcolepsy in persons vaccinated with Pandemrix.
After careful consideration, the CHMP concluded that the data presented by the Finnish researchers are preliminary and that the evidence presented so far is insufficient to allow conclusions to be drawn, and does not lead to any new concerns regarding Pandemrix or other vaccines, including other influenza vaccines. On the basis of the current evidence, the role of the Pandemrix antigen and its adjuvant on the association between Pandemrix and narcolepsy remains unknown.
https://www.ema.europa.eu/en/news/european-medicines-agency-reviews-hypothesis-onpandemrix-development-narcolepsy[[Gebruiker:Jc kortekaas apotheker|Jc kortekaas apotheker]] ([[Overleg gebruiker:Jc kortekaas apotheker|overleg]]) 6 jan 2021 18:52 (CET)
| |||